Overview

A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults

Status:
Completed

Trial end date:
2008-09-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the safety and efficacy of various doses of VI-0521 compared to both placebo, and the single-agent components that comprise each combination dose. This study will provide confirmatory data to demonstrate that doses of VI-0521 have efficacy that is greater than placebo and each of the single-agent components that comprise the combination dose.

Phase:

Phase 3

Details

Lead Sponsor:

VIVUS, Inc.

Collaborator:

Medpace, Inc.

Treatments:

Phentermine
Topiramate